Search Results - "Bhandari, Manish"

Dynamic Fracture Analysis of Functionally Graded Material Structures – A Critical Review by Bhandari, Manish, Purohit, Kamlesh

“…In recent decades, the crack problem of FGMs has attracted a significant amount of attention. In this paper investigations published since year 2000 are…”
Get full text

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? by BHANDARI, Manish S, CROOK, Juanita, HUSSAIN, Maha

“…For several decades, androgen deprivation (AD) has been the mainstay for treating metastatic prostate cancer. AD can be attained by a variety of means;…”
Get full text

Epothilones and the next generation of phase III trials for prostate cancer by Bhandari, Manish S., Hussain, Maha

Get full text

Clinical trials in metastatic prostate cancer – Has there been real progress in the past decade? by Bhandari, Manish S., Petrylak, Daniel P., Hussain, Maha

“…Hormone refractory prostate cancer remains a challenge. While only palliative treatment strategies were available for the past several decades, many promising…”
Get full text

Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review by Rachna Raman, Philip D. Leming, Manish Bhandari, Daniel Long, Michael B. Streiff

“…This study systematically reviews outcomes after inferior vena cava (IVC) filtration in cancer-associated venous thromboembolism (VTE). A comprehensive review…”
Get full text

Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone‐refractory prostate carcinoma by Bhandari, Manish S., Pienta, Kenneth J., Fardig, Judith, Olson, Karin, Smith, David C.

“…BACKGROUND The current study evaluated the efficacy of oral uracil/tegafur (UFT) and leucovorin (LV) in patients with hormone‐refractory metastatic prostrate…”
Get full text

CHECKPOINT INHIBITION WITH NIVOLUMAB IN MALIGNANT MESOTHELIOMA: A BREATH OF FRESH AIR FOR A STAGNATING DISEASE by JONES, RILEY, KARTHIK, FELIX, DESAI, KALPAN, BHANDARI, MANISH

Get full text

Layout improvement of railway workshop using systematic layout planning (SLP) – A case study by Khariwal, Shubham, Kumar, Pradeep, Bhandari, Manish

“…Railways workshop is responsible for periodic overhauling of coaching stock and serves as a base for manufacturing, repairing and supply parts to Sheds/Depots…”
Get full text

Abstract P038: Early phase II clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in adolescents and young adults (AYA) with brain cancers by Morgan, Lee Roy, Weiner, Roy S., Mahmood, Tallat, Ware, Marcus L., Rodgers, Andrew H., Bhandari, Manish, Friendlander, Philip

“…Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of…”
Get full text

Abstract CT181: Phase I/II clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) as treatment for adolescents and young adults (AYA) with cancers involving the CNS by Morgan, Lee Roy, Weiner, Roy S., Mahmood, Tallat, Ware, Marcus, Rodgers, Andrew H., Bhandari, Manish, Friedlander, Philip

“…Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of…”
Get full text

Abstract CT152: Phase II clinical trial results for 4-demethyl-4-cholesteryloxycarbonyl-penclomedine (DM-CHOC-PEN) in advanced non-small cell lung cancer (NSCLC) involving the CNS by Weiner, Roy S., Morgan, Lee Roy, Ware, Marcus, Mahmood, Tallat, Gordon, Craig, Bhandari, Manish, Rodgers, Andrew, Matrana, Marc, Cosgriff, Thomas M., Friedlander, Philip, Zou, Jay J.

“…Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of…”
Get full text

Abstract CT101: Phase I clinical trial: results from the use of 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation as treatment for cancers involving the CNS by DiBiase, Steven J., Weiner, Roy S., Mahmood, Tallat, Harris, Kendra, Kawauchi, Ronald, Devisetty, Kiran, Herman, James, Bhandari, Manish, Ware, Marcus, Friedlander, Paul, Morgan, Lee R., Baghian, Ali

“…Purpose: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of…”
Get full text

Abstract A086: Early clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in adolescents and young adults (AYA) with cancers by Morgan, Lee Roy, Rodgers, Andrew H., Weiner, Roy S., Mahmood, Tallat, Ware, Marcus L., Bhandari, Manish, Friedlander, Philip

“…Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of…”
Get full text

Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial by Ejlertsen, Bent, Barrios, Carlos H., Gokmen, Erhan, Robert, Nicholas, Martinez, Noelia, Link, John S., Morales, Serafin, Ruiz Borrego, Manuel, Bhandari, Manish, Rai, Yoshiaki, Luczak, Adam, Fujita, Takashi, Wong, Alvin, Yao, Bin, Martin, Miguel

“…Abstract only…”
Get full text

Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes by Jones, Riley G, Karthik, Felix, Dugar, Anushree, Kanagarajan, Karthik, Desai, Kalpan, Bhandari, Manish

“…BACKGROUND Malignant pleural mesothelioma (MPM) is a highly lethal cancer with a median survival of ~12 months even with aggressive intervention. Frontline…”
Get full text

ACTR-51. PRELIMINARY SUPPORT FOR 4-DEMETHYL-4-CHOLESTERYLOXYCARBONYLPENCLOMEDINE (DM-CHOC-PEN) AS A CHEMOSENSITIZER IN CANCERS INVOLVING THE CNS by Ware, Marcus, Weiner, Roy, Mahmood, Tallat, Kawauchi, Ronald, Rogers, AH, Morgan, Lee Roy, Devisetty, Kiran, Zou, Jay Jiguang, Bhandari, Manish, Summe, Robert, Herman, James, Weber, Judy

Get full text

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study by Kumar, Shaji, Flinn, Ian W, Noga, Stephen J., Hari, Parameswaran, Rifkin, Robert M., Callander, Natalie Scott, Bhandari, Manish, Wolf, Jeffrey Lee, Gasparetto, Cristina, Krishnan, Amrita, Grosman, Daren D, Glass, Jonathan, Sahovic, Entezam Asim, Shi, Hongliang, Webb, Iain J., Richardson, Paul, Rajkumar, S. Vincent

“…Background: Combination regimens incorporating bortezomib (VELCADE®, Vc), lenalidomide (REVLIMID®, Rev), dexamethasone (Dex) and cyclophosphamide (Cy) (Vc–Dex,…”
Get full text

A genetic revolution in healthcare by Bhandari, M, Garg, R, Glassman, R, Ma, P C, Zemmel, R W

Get more information